Novo Nordisk's Commitment to India's Diabetes Care

In a significant announcement, Novo Nordisk has confirmed that its flagship insulin brand, Mixtard, will continue to be available in India in vial form. This decision comes as the company phases out other delivery formats, including Penfill cartridges, addressing concerns over the discontinuation of widely used insulin products.

Consolidation for Greater Reach

Novo Nordisk explained that the consolidation of its insulin portfolio is aimed at meeting increasing patient demand and ensuring a stable supply. "This strategic move allows us to expand our reach to millions more patients in the coming decade," the company stated, acknowledging the potential disruption to current users.

Global Strategy Shift

The Danish pharmaceutical giant is focusing on newer, more profitable treatments like Ozempic and Wegovy, planned for introduction in India this year. As part of this global shift, older-generation insulin products are being gradually phased out worldwide, with Mixtard and other human insulins remaining accessible in vials across India.